Jump to ContentJump to Main Navigation
Show Summary Details
In This Section

Journal of Translational Internal Medicine

4 Issues per year

Open Access
Online
ISSN
2224-4018
See all formats and pricing
In This Section

Viral hepatitis in hemodialysis: An update

Professor Bassam Bernieh
  • Tawam Hospital in Affiliation with Johns Hopkins Medicine, COMHS, UAE University, Al Ain, UAE
  • Email:
Published Online: 2015-09-30 | DOI: https://doi.org/10.1515/jtim-2015-0018

Abstract

Hepatitis outbreaks in hemodialysis (HD) patients and staff were reported in the late 1960s, and a number of hepatotropic viruses transmitted by blood and other body fluids have been identified. Hepatitis B virus (HBV) was the first significant hepatotropic virus to be identified in HD centers. HBV infection has been effectively controlled by active vaccination, screening of blood donors, the use of erythropoietin and segregation of HBV carriers. Hepatitis delta virus is a defective virus that can only infect HBV-positive individuals. Hepatitis C virus (HCV) is the most significant cause of non-A, non-B hepatitis and is mainly transmitted by blood transfusion. The introduction in 1990 of routine screening of blood donors for HCV contributed significantly to the control of HCV transmission. An effective HCV vaccine remains an unsolved challenge; however, pegylation of interferon-alfa has made it possible to treat HCV-positive dialysis patients. Unexplained sporadic outbreaks of hepatitis by the mid-1990s prompted the discovery of hepatitis G virus, hepatitis GB virus C and the TT virus. The vigilant observation of guidelines on universal precaution and regular virologic testing are the cornerstones of the effective control of chronic hepatitis in the setting of HD. Major recent advances in the viral diagnosis technology and the development of new oral, direct-acting antiviral agents allow early diagnosis and better therapeutic response. The current update will review the recent developments, controversies and new treatment of viral hepatitis in HD patients.

Keywords: DAAs; hemodialysis; hepatitis B; hepatitis C; occult HBV; viral hepatitis

References

  • 1. Karkar A, Abdelrahman M, Ghacha R, Malik TQ. Prevention of Viral Transmission in HD Units: The value of isolation. Saudi J Kidney Dis Transpl 2006;17:183-8.

  • 2. Fabrizi F, Marcelli D, Bacchini G, Guarnori I, Erba G, Locatelli F. Antibodies to hepatitis C virus (HCV) in chronic renal failure (CRF) patients on conservative therapy: Prevalence, risk factors and relationship to liver disease. Nephrol Dial Transplant 1994;9:780-4.

  • 3. Fabrizi F, Raffaele L, Bacchini G, Guarnori I, Pontoriero G, Erba G, et al. Antibodies to hepatitis C virus (HCV) and transaminase concentration in chronic haemodialysis patients: A study with second-generation assays. Nephrol Dial Transplant 1993;8:744-7.

  • 4. Simons JN, Pilot-Matias TJ, Leary TP, Dawson GJ, Desai SM, Schlauder GG, et al. Identification of two flavivirus-like genomes in the GB hepatitis agent. Proc Natl Acad Sci USA 1995;92:3401-5. [Crossref]

  • 5. Linnen J, Wages JJ, Zhang-Keck ZY, Fry KE, Krawczynski KZ, Alter H, et al. Molecular cloning and disease association of hepatitis G virus: A transfusion-transmissible agent. Science 1996;271:505-8. [Crossref]

  • 6. Zuckerman AJ. Alphabet of hepatitis viruses. Lancet 1996;347:558-9. [Crossref]

  • 7. Miyakawa Y, Mayumi M. Hepatitis G virus - A true hepatitis virus or an accidental tourist? N Engl J Med 1997;336:795-6. [Crossref]

  • 8. Nishizawa T, Okamoto H, Konishi K, Yoshizawa H, Miyakawa Y, Mayumi M. A novel DNA virus (TTV) associated with elevated transaminase levels in posttransfusion hepatitis of unknown etiology. Biochem Biophys Res Commun 1997;241:92-7. [Crossref]

  • 9. Proceedings of the European Association for the Study of the Liver (EASL) International Consensus Conference on Hepatitis B. September 14-16, 2002. Geneva, Switzerland. J Hepatol 2003;39 Suppl 1:S1-235.

  • 10. Moloughney BW. Transmission and postexposure management of bloodborne virus infections in the health care setting: Where are we now? CMAJ 2001;165:445-51.

  • 11. Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008;359:1486-500. [Crossref]

  • 12. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004;11:97-107.

  • 13. Kane M. Global programme for control of hepatitis B infection. Vaccine 1995;13 Suppl 1:S47-9. [Crossref]

  • 14. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:153-6.

  • 15. Rosenheim Advisory Group. Hepatitis and the Treatment of Chronic Renal Failure. London: Department of Health and Social Security; 1972.

  • 16. Centers for Disease Control. Hepatitis: Control Measures for Hepatitis B in Dialysis Centers. HEW publication no. (CDC) 78-8358. Altlanta, GA: US Department of Health, Education and Welfare; 1977.

  • 17. Dinits-Pensy M, Forrest GN, Cross AS, Hise MK. The use of vaccines in adult patients with renal disease. Am J Kidney Dis 2005;46:997-1011. [Crossref]

  • 18. Stevens CE, Szmuness W, Goodman AI, Weseley SA, Fotino M. Hepatitis B vaccine: Immune responses in haemodialysis patients. Lancet 1980;2:1211-3. [Crossref]

  • 19. Desmyter J, Colaert J, De Groote G, Reynders M, Reerink-Brongers EE, Lelie PN, et al. Efficacy of heat-inactivated hepatitis B vaccine in haemodialysis patients and staff. Double-blind placebo-controlled trial. Lancet 1983;2:1323-8. [Crossref]

  • 20. Finelli L, Miller JT, Tokars JI, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial 2005;18:52-61.

  • 21. Burdick RA, Bragg-Gresham JL, Woods JD, Hedderwick SA, Kurokawa K, Combe C, et al. Patterns of hepatitis B prevalence and seroconversion in hemodialysis units from three continents: The DOPPS. Kidney Int 2003;63:2222-9. [Crossref]

  • 22. Johnson DW, Dent H, Yao Q, Tranaeus A, Huang CC, Han DS, et al. Frequencies of hepatitis B and C infections among haemodialysis and peritoneal dialysis patients in Asia-Pacific countries: Analysis of registry data. Nephrol Dial Transplant 2009;24:1598-603.

  • 23. Yakaryilmaz F, Gurbuz OA, Guliter S, Mert A, Songur Y, Karakan T, et al. Prevalence of occult hepatitis B and hepatitis C virus infections in Turkish hemodialysis patients. Ren Fail 2006;28:729-35. [Crossref]

  • 24. Ferreira RC, Teles SA, Dias MA, Tavares VR, Silva SA, Gomes SA, et al. Hepatitis B virus infection profile in hemodialysis patients in Central Brazil: Prevalence, risk factors, and genotypes. Mem Inst Oswaldo Cruz 2006;101:689-92. [Crossref]

  • 25. Carrilho FJ, Moraes CR, Pinho JR, Mello IM, Bertolini DA, Lemos MF, et al. Hepatitis B virus infection in Haemodialysis Centres from Santa Catarina State, Southern Brazil. Predictive risk factors for infection and molecular epidemiology. BMC Public Health 2004;4:13. [Crossref]

  • 26. Almawi WY, Qadi AA, Tamim H, Ameen G, Bu-Ali A, Arrayid S, et al. Seroprevalence of hepatitis C virus and hepatitis B virus among dialysis patients in Bahrain and Saudi Arabia, Transplant Proc 2004;36:1824-6.

  • 27. Ribot S, Rothstein M, Goldblat M, Grasso M. Duration of hepatitis B surface antigenemia (HBs Ag) in hemodialysis patients. Arch Intern Med 1979;139:178-80. [Crossref]

  • 28. Hollinger FB, Sood G. Occult hepatitis B virus infection: A covert operation. J Viral Hepat 2010;17:1-15.

  • 29. Torbenson M, Thomas DL. Occult hepatitis B infection. Lancet Infect Dis 2003;2:479-86.

  • 30. Aghakhani A, Banifazl M, Kalantar E, Eslamifar A, Ahmadi F, Razeghi E, et al. Occult hepatitis B virus infection in hemodialysis patients with isolated hepatitis B core antibody: A multicenter study. Ther Apher Dial 2010;14:349-53. [Crossref]

  • 31. Gutiérrez-García ML, Fernandez-Rodriguez CM, Lledo-Navarro JL, Buhigas-Garcia I. Prevalence of occult hepatitis B virus infection. World J Gastroenterol 2011;17:1538-42. [Crossref]

  • 32. Hu KQ. Occult hepatitis B virus infection and its clinical implications. J Viral Hepat 2002;9:243-57.

  • 33. Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection. J Hepatol 2007;46:160-70. [Crossref]

  • 34. Lee WM. Hepatitis B virus infection. N Engl J Med 1997;337:1733-45. [Crossref]

  • 35. Lok AS. Chronic hepatitis B. N Engl J Med 2002;346:1682-3.

  • 36. Alavian SM, Bagheri-Lankarani K, Mahdavi-Mazdeh M, Nourozi S. The changing epidemiology of viral hepatitis B in Iran. Hemodial Int 2008;12:378-82. [Crossref]

  • 37. Alter MJ, Hadler SC, Margolis HS, Alexander WJ, Hu PY, Judson FN, et al. The changing epidemiology of hepatitis B in the United States. Need for alternative vaccination strategies. JAMA 1990;263:1218-22. [Crossref]

  • 38. Marrero JA, Lok AS. Occult hepatitis B virus infection in patients with hepatocellular carcinoma: Innocent bystander, cofactor, or culprit? Gastroenterology 2004;126:347-50. [Crossref]

  • 39. Brechot P. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: Clinically significant or purely “occult”? Hepatology 2001;34:194-203. [Crossref]

  • 40. Carman WF. The clinical significance of surface antigen variants of hepatitis B virus. J Viral Hepat 1997;4 Suppl 1:11-20.

  • 41. Zuckerman AJ. Effect of hepatitis B virus mutants on efficacy of vaccination. Lancet 2000;355:1382-4. [Crossref]

  • 42. Liang TJ, Blum HE, Wands JR. Characterization and biological properties of a hepatitis B virus isolated from a patient. Hepatology 1990;12:204-12. [Crossref]

  • 43. Ackerman Z, Wands JR, Gazitt Y, Brechot C, Kew MC, Shouval D. Enhancement of HBsAg detection in serum of patients with chronic liver disease following removal of circulating immune complexes. J Hepatol 1994;20:398-404. [Crossref]

  • 44. Grob P, Jilg W, Bornhak H, Gerken G, Gerlich W, Günther S, et al. Serological pattern “anti-HBc alone”: Report on a workshop. J Med Virol 2000;62:450-5. [Crossref]

  • 45. Hamkar R, Aghakhani A, Soufian S, Banifazl M, Ghavami N, Nadri M, et al. Surface gene mutations of hepatitis B virus among high-risk patients with occult hepatitis B virus infection. Diagn Microbiol Infect Dis 2010;66:285-91. [Crossref]

  • 46. Mrani S, Chemin I, Menouar K, Guillaud O, Pradat P, Borghi G, et al. Occult HBV infection may represent a major risk factor of non-response to antiviral therapy of chronic hepatitis C. J Med Virol 2007;79:1075-81. [Crossref]

  • 47. Fabrizi F, Messa PG, Lunghi G, Aucella F, Bisegna S, Mangano S, et al. Occult hepatitis B virus infection in dialysis patients: A multicentre survey. Aliment Pharmacol Ther 2005;21:1341-7. [Crossref]

  • 48. Kanbay M, Gur G, Akcay A, Selcuk H, Yilmaz U, Arslan H, et al. Is hepatitis C virus positivity a contributing factor to occult hepatitis B virus infection in hemodialysis patients? Dig Dis Sci 2006;51:1962-6. [Crossref]

  • 49. Besisik F, Karaca C, Akyüz F, Horosanli S, Onel D, Badur S, et al. Occult HBV infection and YMDD variants in hemodialysis patients with chronic HCV infection. J Hepatol 2003;38:506-10. [Crossref]

  • 50. Cooreman MP, Leroux-Roels G, Paulij WP. Vaccine and hepatitis B immune globulin-induced escape mutations of hepatitis B virus surface antigen. J Biomed Sci 2001;8:237-47. [Crossref]

  • 51. Weinberger KM, Bauer J, Bohm S, Jilg W. High genetic variability of the group-specific a determinant of hepatitis B surface antigen (HBsAg) and the corresponding fragment of the viral polymerase in chronic virus carriers lacking detectable HBsAg in serum. J Gen Virol 2000;81:1165-74. [Crossref]

  • 52. Cabrerizo M, Bartolome J, Caramelo C, Barril G, Carreno V. Molecular analysis of hepatitis B virus DNA in serum and peripheral blood mononuclear cells from hepatitis B surface antigen-negative cases. Hepatology 2000;32:116-23. [Crossref]

  • 53. Oesterreicher C, Hammer J, Koch U, Pfeffel F, Sunder-Plassmann G, Petermann D, et al. HBV and HCV genome in peripheral blood mononuclear cells in patients undergoing chronic hemodialysis. Kidney Int 1995;48:1967-71. [Crossref]

  • 54. Minuk GY, Sun DF, Greenberg R, Zhang M, Hawkins K, Uhanova J, et al. Occult hepatitis B virus infection in a North American adult hemodialysis patient population. Hepatology 2004;40:1072-7. [Crossref]

  • 55. Dumaidi K, Al-Jawabreh A. Prevalence of occult HBV among hemodialysis patients in two districts in the northern part of the West Bank, Palestine. J Med Virol 2014;86:1694-9. [Crossref]

  • 56. Abu El Makarem MA, Abdel Hamid M, Abdel Aleem A, Ali A, Shatat M, Sayed D, et al. Prevalence of Occult Hepatitis B Virus Infection in Hemodialysis Patients From Egypt With or Without Hepatitis C Virus Infection. Hepat Mon 2012;12:253-8.

  • 57. Yakaryilmaz F, Gurbuz OA, Guliter S, Mert A, Songur Y, Karakan T, et al. Prevalence of occult hepatitis B and hepatitis C virus infections in Turkish hemodialysis patients. Ren Fail 2006;28:729-35. [Crossref]

  • 58. Motta JS, Mello FC, Lago BV, Perez RM, Gomes SA, Figueiredo FF. Occult hepatitis B virus infection and lamivudine-resistant mutations in isolates from renal patients undergoing hemodialysis. J Gastroenterol Hepatol 2010;25:101-6. [Crossref]

  • 59. Sav T, Gursoy S, Torun E, Sav NM, Unal A, Oymak O, et al. Occult HBV infection in continuous ambulatory peritoneal dialysis and hemodialysis patients. Ren Fail 2010;32:74-7. [Crossref]

  • 60. Shih CM, Lo SJ, Miyamura T, Chen SY, Wu LY. Suppression of hepatitis B virus expression and replication by hepatitis C virus core protein in HuH-7 cells. J Virol 1993;67:5823-32.

  • 61. Chu CM, Yeh CT, Liaw YF. Low-level viremia and intracellular expression of hepatitis B surface antigen (HBsAg) in HBsAg carriers with concurrent hepatitis C infection. J Clin Microbiol 1998;36:2084-6.

  • 62. Sheen IS, Liaw YF, Chu CM, Pao CC. Role of hepatitis C virus infection in spontaneous hepatitis B surface antigen clearance during chronic hepatitis B virus infection. J Infect Dis 1992;165:831-4. [Crossref]

  • 63. Koike K, Kobayashi M, Gondo M, Hayashi I, Osuga T, Takada S. Hepatitis B virus DNA is frequently found in liver biopsy samples from hepatitis C virus-infected chronic hepatitis patients. J Med Virol 1998;54:249-55. [Crossref]

  • 64. Paterlini P, Driss F, Nalpas B, Pisi E, Franco D, Berthelot P, et al. Persistence of hepatitis B and hepatitis C viral genomes in primary liver cancers from HBsAg-negative patients: A study of a low-endemic area. Hepatology 1993;17:20-9. [Crossref]

  • 65. Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999;341:22-6.

  • 66. Siagris D, Christofidou M, Triga K, Pagoni N, Theocharis GJ, Goumenos D, et al. Occult hepatitis B virus infection in hemodialysis patients with chronic HCV infection. J Nephrol 2006;19:327-33.

  • 67. Tang S, Lai KN. Chronic viral hepatitis in hemodialysis patients. Hemodial Int 2005;9:169-79. [Crossref]

  • 68. Winearls CG. Recombinant human erythropoietin: 10 years of clinical experience. Nephrol Dial Transplant 1998;13 Suppl 2:3-8. Centers for Disease Control (CDC). Update: Universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus and other blood-borne pathogens in healthcare settings. MMWR Morb Mortal Wkly Rep 1988;37:377-82.

  • 69. Krugman S, Giles JP, Hammond J. Viral hepatitis, type B (MS-2 strain) prevention with specific hepatitis B immune serum globulin. JAMA 1971;218:1665-70. [Crossref]

  • 70. Buynak EB, Roehm RR, Tytell AA, Bertland AU, Lampson GP, Hilleman MR. Vaccine against human hepatitis B. JAMA 1976;235:2832-4. [Crossref]

  • 71. Adkins JC, Wagstaff AJ. Recombinant hepatitis B vaccine: A review of its immunogenicity and protective efficacy against hepatitis B. BioDrugs 1998;10:137-58. [Crossref]

  • 72. Zuckerman JN, Sabin C, Craig FM, Williams A, Zuckerman AJ. Immune response to a new hepatitis B vaccine in healthcare workers who had not responded to standard vaccine: Randomised double blind dose-response study. BMJ 1997;314:329-33. [Crossref]

  • 73. Andre FE. Overview of a 5-year clinical experience with a yeastderived hepatitis B vaccine. Vaccine 1990;8 Suppl:S74-8.

  • 74. McMahon BJ, Helminiak C, Wainwright RB, Bulkow L, Trimble BA, Wainwright K. Frequency of adverse reactions to hepatitis B vaccine in 43 618 persons. Am J Med 1992;92:254-6.

  • 75. Peces R, De La Torre M, Alcazar R, Urra JM. Prospective analysis of the factors influencing the antibody response to hepatitis B vaccine in hemodialysis patients. Am J Kidney Dis 1997;29:239-45. [Crossref]

  • 76. Fraser GM, Ochana N, Fenyves D, Neumann L, Chazan R, Niv Y, et al. Increasing serum creatinine and age reduce the response to hepatitis B vaccine in renal failure patients. J Hepatol 1994;21:450-4. [Crossref]

  • 77. Evans TG, Schiff M, Graves B, Agosti J, Barritt ML, Garner D, et al. The safety and efficacy of GM-CSF as an adjuvant in hepatitis B vaccination of chronic hemodialysis patients who have failed primary vaccination. Clin Nephrol 2000;54:138-42.

  • 78. Jungers P, Devillier P, Salomon H, Cerisier JE, Courouce AM. Randomised placebo-controlled trial of recombinant interleukin-2 in chronic uraemic patients who are non-responders to hepatitis B vaccine. Lancet 1994;344:856-7. [Crossref]

  • 79. Kong NC, Beran J, Kee SA, Miguel JL, Sánchez C, Bayas JM, et al. A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients. Kidney Int 2008;73:856-62. [Crossref]

  • 80. Mettang T, Schenk U, Thomas S, Machleidt C, Kiefer T, Fischer FP, et al. Low-dose intradermal versus intramuscular hepatitis B vaccination in patients with end-stage renal failure: A preliminary study. Nephron 1996;72:192-19.

  • 81. Fabrizi F, Andrulli S, Bacchini G, Corti M, Locatelli F. Intradermal versus intra muscular hepatitis B re-vaccination in non-responsive chronic dialysis patients: A prospective, randomized study with cost-effectiveness evaluation. Nephrol Dial Transplant 1997;12:1204-11.

  • 82. Wong PN, Mak SK, Wong AK. Management of chronic hepatitis B infection in patients with end-stage renal disease and dialysis. Hep B Annual 2006;3:76-105.

  • 83. Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet 2003;362:2089-94. [Crossref]

  • 84. Wong PN, Fung TT, Mak SK, Lo KY, Tong GM, Wong Y, et al. Hepatitis B virus infection in dialysis patients. J Gastroenterol Hepatol 2005;20:1641-51. [Crossref]

  • 85. Petersen J, Buti M. Considerations for the long-term treatment of chronic hepatitis B with nucleos(t)ide analogs. Expert Rev Gastroenterol Hepatol 2012;6:683-94. [Crossref]

  • 86. Pipili C, Cholongitas E, Papatheodoridis G. Review article: Nucleos(t) ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease. Aliment Pharmacol Ther 2014;39:35-46. [Crossref]

  • 87. Hepatitis C. WHO Publication, Fact sheet N°164, Updated April 2014.

  • 88. Angelico M, Renganathan E, Gandin C, Fathy M, Profili MC, Refai W, et al. Chronic liver disease in the Alexandria governorate, Egypt: Contribution of schistosomiasis and hepatitis virus infections. J Hepatol 1997;26:236-43. [Crossref]

  • 89. Madhava V, Burgess C, Drucker E. Epidemiology of chronic hepatitis C virus infection in sub-Saharan Africa. Lancet Infect Dis 2002;2:293-302. [Crossref]

  • 90. Cornberg M, Razavi HA, Alberti A, Bernasconi E, Buti M, Cooper C, et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int 2011;31 Suppl 2:30-60. Khedmat H, Amini M, Ghamar-Chehreh ME, Agah S. Hepatitis C virus infection in dialysis patients. Saudi J Kidney Dis Transpl 2014;25:1-8. [Crossref]

  • 91. Simmonds P. Viral heterogeneity of the hepatitis C virus. J Hepatol 1999;31 Suppl 1:54-60. [Crossref]

  • 92. Nguyen MH, Keeffe EB. Chronic hepatitis C: genotypes 4 to 9. Clin Liver Dis 2005;9:411-26, vi.

  • 93. Nicot F, Legrand-Abravanel F, Sandres-Saune K, Boulestin A, Dubois M, Alric L, et al. Heterogeneity of hepatitis C virus genotype 4 strains circulating in south-western France. J Gen Virol 2005;86:107-14. [Crossref]

  • 94. Argentini C, Dettori S, Villano U, Guadagnino V, Infantolino D, Dentico P, et al. Molecular characterisation of HCV genotype 4 isolates circulating in Italy. J Med Virol 2000;62:84-90. [Crossref]

  • 95. Ray SC, Arthur RR, Carella A, Bukh J, Thomas DL. Genetic epidemiology of hepatitis C virus throughout egypt. J Infect Dis 2000;182:698-707. [Crossref]

  • 96. Shobokshi OA, Serebour FE, Skakni L, Al-Saffy YH, Ahdal MN. Hepatitis C genotypes and subtypes in Saudi Arabia. J Med Virol 1999;58:44-8. [Crossref]

  • 97. Oni AO, Harrison TJ. Genotypes of hepatitis C virus in Nigeria. J Med Virol 1996;49:178-86. [Crossref]

  • 98. Singh S, Malhotra V, Sarin SK. Distribution of hepatitis C virus genotypes in patients with chronic hepatitis C infection in India. Indian J Med Res 2004;119:145-8.

  • 99. Wantuck JM, Ahmed A, Nguyen MH. The epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6. Aliment Pharmacol Ther 2014;39:137-47. [Crossref]

  • 100. Khedmat H, Amini M, Ghamar-Chehreh ME, Agah S. Hepatitis C virus infection in dialysis patients. Saudi J Kidney Dis Transpl 2014;25:1-8.

  • 101. Wreghitt TG. Blood-borne virus infections in dialysis units - A review. Rev Med Virol 1999;9:101-9. [Crossref]

  • 102. Bernieh B, Al Shaebi F, Jean N, Hassanin S, Wafa A, Tabbakh A, et al. Successful control of Hepatitis C infection in hemodialysis unit by complete isolation: Ten years’ experience of Medinah Al Munawarah. Saudi Society of Nephrology Annual Meeting, Jeddah, KSA, February 2007.

  • 103. Jadoul M, Poignet JL, Geddes C, Locatelli F, Medin C, Krajewska M, et al, HCV Collaborative Group: The changing epidemiology of hepatitis C virus (HCV) infection in haemodialysis: European multicentre study. Nephrol Dial Transplant 2004;19:904-9.

  • 104. Gallego E, Lopez A, Perez J, Llamas F, Lorenzo I, Lopez E, et al. Effect of isolation measures on the incidence and prevalence of hepatitis C virus infection in hemodialysis. Nephron Clin Pract 2006;104:c1-6. [Crossref]

  • 105. Yang CS, Chang HH, Chou CC, Peng SJ. Isolation effectively prevents the transmission of hepatitis C virus in the hemodialysis unit. J Formos Med Assoc 2003;102:79-85.

  • 106. Barril G, Traver JA. Decrease in the hepatitis C virus (HCV) prevalence in hemodialysis patients in Spain: Effect of time, initiating HCV prevalence studies and adoption of isolation measures. Antiviral Res 2003;60:129-34. [Crossref]

  • 107. Saxena AK, Panhotra BR, Sundaram DS, Naguib M, Venkateshappa CK, Uzzaman W, et al. Impact of dedicated space, dialysis equipment, and nursing staff on the transmission of hepatitis C virus in a hemodialysis unit of the middle east. Am J Infect Control 2003;31:26-33. [Crossref]

  • 108. Valtuille R, Moretto H, Lef L, Rendo P, Fernandez JL. Decline of high hepatitis C virus prevalence in a hemodialysis unit with no isolation measures during a 6-year follow-up. Clin Nephrol 2002;57:371-5. [Crossref]

  • 109. Aucella F, Vigilante M, Valente GL, Stallone C. Systematic monitor disinfection is effective in limiting HCV spread in hemodialysis. Blood Purif 2000;18:110-4. [Crossref]

  • 110. Buturovic-Ponikvar J. Expert Group for Dialysis in Slovenia at the Ministry of Health, Republic of Slovenia: Renal replacement therapy in Slovenia: Annual report 2001. Nephrol Dial Transplant 2003;8 Suppl 5:v53-5.

  • 111. Omar MN, Tashkandy MA. Liver enzyme and protein electrophoretic pattern in hemodialysis patients with antibodies against the hepatitis C virus. Saudi Med J 2003;2:S122.

  • 112. Bernieh B, Allam M, Halepota A, Mohamed AO, Parkar J, Tabbakh A. Prevalence of hepatitis C virus antibodies in hemodialysis patients in madinah Al munawarah. Saudi J Kidney Dis Transpl 1995;6:132-5.

  • 113. Othman B, Monem F. Prevalence of antibodies to hepatitis C virus among hemodialysis patients in Damascus, Syria. Infection 2001;29:262-5. [Crossref]

  • 114. Gul A, Iqbal F. Prevalence of hepatitis C in patients on maintenance haemodialysis. J Coll Physicians Surg Pak 2003;13:15-8.

  • 115. Ansar MM, Kooloobandi A. Prevalence of hepatitis C virus infection in thalassemia and haemodialysis patients in north Iran-Rasht. J Viral Hepat 2002;9:390-2.

  • 116. Ben Othman S, Bouzgarrou N, Achour A, Bourlet T, Pozzetto B, Trabelsi A. High prevalence and incidence of hepatitis C virus infections among dialysis patients in the East-Centre of Tunisia. Pathol Biol (Paris) 2004;52:323-7. [Crossref]

  • 117. Diouf ML, Diouf B, Niang A, Ka EH, Pouye A, Seck A, et al. Prevalence of hepatitis B and C viruses in a chronic hemodialysis center in Dakar. Dakar Med 2000;45:1-4.

  • 118. Covic A, Iancu L, Apetrei C, Scripcaru D, Volovat C, Mititiuc I, et al. Hepatitis virus infection in haemodialysis patients from Moldavia. Nephrol Dial Transplant 1999;14:40-5.

  • 119. Ahmetagic S, Muminhodzic K, Cickusic E, Stojic V, Petrovic J, Tihic N. Hepatitis C infection in risk groups. Bosn J Basic Med Sci 2006;6:13-7.

  • 120. Carneiro MA, Martins RM, Teles SA, Silva SA, Lopes CL, Cardoso DD, et al. Hepatitis C prevalence and risk factors in hemodialysis patients in Central Brazil: A survey by polymerase chain reaction and serological methods. Mem Inst Oswaldo Cruz 2001;96:765-9. [Crossref]

  • 121. Sanchez JL, Sjogren MH, Callahan JD, Watts DM, Lucas C, Abdel- Hamid M, et al. Hepatitis C in Peru: Risk factors for infection, potential iatrogenic transmission, and genotype distribution. Am J Trop Med Hyg 2000;63:242-8.

  • 122. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007;13:2436-41. [Crossref]

  • 123. Rahnavardi M, Hosseini Moghaddam SM, Alavian SM. Hepatitis C in hemodialysis patients: Current global magnitude, natural history, diagnostic difficulties, and preventive measures. Am J Nephrol 2008;28:628-40. [Crossref]

  • 124. El-Amin HH, Osman EM, Mekki MO, Abdelraheem MB, Ismail MO, Yousif ME, et al. Hepatitis C virus infection in hemodialysis patients in Sudan: Two centers’ report. Saudi J Kidney Dis Transpl 2007;18:101-6.

  • 125. Hmaied F, Ben Mamou M, Saune-Sandres K, Rostaing L, Slim A, Arrouji Z, et al. Hepatitis C virus infection among dialysis patients in Tunisia: Incidence and molecular evidence for nosocomial transmission. J Med Virol 2006;78:185-91. [Crossref]

  • 126. Petrosillo N, Gilli P, Serraino D, Dentico P, Mele A, Ragni P, et al. Prevalence of infected patients and understaffing have a role in hepatitis C virus transmission in dialysis. Am J Kidney Dis 2001;37:1004-10. [Crossref]

  • 127. Schneeberger PM, Keur I, van Loon AM, Mortier D, de Coul KO, van Haperen AV, et al. The prevalence and incidence of hepatitis C virus infections among dialysis patients in the Netherlands: A nationwide prospective study. J Infect Dis 2000;182:1291-9. [Crossref]

  • 128. Salama G, Rostaing L, Sandres K, Izopet J. Hepatitis C virus infection in French hemodialysis units: A multicenter study. J Med Virol 2000;61:44-51. [Crossref]

  • 129. Sypsa V, Psichogiou M, Katsoulidou A, Skoutelis G, Moutafis S, Hadjiconstantinou V, et al. Incidence and patterns of hepatitis C virus seroconversion in a cohort of hemodialysis patients. Am J Kidney Dis 2005;45:334-43. [Crossref]

  • 130. Fissell RB, Bragg-Gresham JL, Woods JD, Jadoul M, Gillespie B, Hedderwick SA, et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: The DOPPS. Kidney Int 2004;65:2335-42. [Crossref]

  • 131. Fabrizi F, Martin P, Dixit V, Brezina M, Russell J, Conrad A, et al. Detection of de novo hepatitis C virus infection by polymerase chain reaction in hemodialysis patients. Am J Nephrol 1999;19:383-8. [Crossref]

  • 132. Saxena AK, Panhotra BR. The susceptibility of patients with type-2 diabetes to hepatitis C virus infection during long-term haemodialysis. Swiss Med Wkly 2003;133:611-8.

  • 133. Ocak S, Duran N, Kaya H, Emir I. Seroprevalence of hepatitis C in patients with type 2 diabetes mellitus and non-diabetic on haemodialysis. Int J Clin Pract 2006;60:670-4.

  • 134. Centers for Disease Control and Prevention: Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCVrelated chronic disease. MMWR Recomm Rep 1998;47:1-39.

  • 135. Centers for Disease Control and Prevention: Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep 2001;50:1-43.

  • 136. Natov SN, Pereira BJ. Routine serologic testing for hepatitis C virus infection should be instituted among dialysis patients. Semin Dial 2000;13:393-8.

  • 137. Rigopoulou EI, Stefanidis I, Liaskos C, Zervou EK, Rizos C, Mina P, et al. HCV-RNA qualitative assay based on transcription mediated amplification improves the detection of hepatitis C virus infection in patients on hemodialysis: Results from five hemodialysis units in central Greece. J Clin Virol 2005;34:81-5. [Crossref]

  • 138. Kalantar-Zadeh K, Miller LG, Daar ES. Diagnostic discordance for hepatitis C virus infection in hemodialysis patients. Am J Kidney Dis 2005;46:290-300. [Crossref]

  • 139. Yen T, Keeffe EB, Ahmed A. The epidemiology of hepatitis C virus infection. J Clin Gastroenterol 2003;36:47-53. [Crossref]

  • 140. Strader DB, Wright T, Thomas DL, Seeff LB. American Association for the Study of Liver Diseases: Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147-71. [Crossref]

  • 141. Hinrichsen H, Leimenstoll G, Stegen G, Schrader H, Folsch UR, Schmidt WE. Prevalence and risk factors of hepatitis C virus infection in haemodialysis patients: A multicentre study in 2796 patients. Gut 2002;51:429-33.

  • 142. Garinis G, Spanakis N, Theodorou V, Gorgoulis V, Manolis E, Karameris A, et al. Comparison of the enzyme-linked immunosorbant assay III, recombinant immunoblot third generation assay, and polymerase chain reaction method in the detection of hepatitis C virus infection in haemodialysis patients. J Clin Lab Anal 1999;13:122-5. [Crossref]

  • 143. Kelley VA, Everett-Kitchens J, Brannon LE, Connor K, Martinez EJ, Pearson TC, et al. Lack of seronegative hepatitis C virus infections in patients with chronic renal failure. Transplantation 2002;74:1473-5. [Crossref]

  • 144. Sullivan DG, Kim SS, Wilson JJ, Stehman-Breen C, Gretch DR. Investigating hepatitis C virus heterogeneity in a high prevalence setting using heteroduplex tracking analysis. J Virol Methods 2001;96:5-16. [Crossref]

  • 145. Courouce AM, Le Marrec N, Bouchardeau F, Razer A, Maniez M, Laperche S, et al. Efficacy of HCV core antigen detection during the preseroconversion period. Transfusion 2000;40:1198-202. [Crossref]

  • 146. Reddy AK, Dakshinamurty KV, Lakshmi V. Utility of HCV core antigen ELISA in the screening for hepatitis C virus infection in patients on hemodialysis. Indian J Med Microbiol 2006;24:55-7.

  • 147. Fabrizi F, Lunghi G, Aucella F, Mangano S, Barbisoni F, Bisegna S, et al. Novel assay using total hepatitis C virus (HCV) core antigen quantification for diagnosis of HCV infection in dialysis patients. J Clin Microbiol 2005;43:414-20. [Crossref]

  • 148. Aoyagi K, Iida K, Ohue C, Matsunaga Y, Tanaka E, Kiyosawa K, et al. Performance of a conventional enzyme immunoassay for hepatitis C virus core antigen in the early phases of hepatitis C infection. Clin Lab 2001;47:119-27.

  • 149. Hosokawa N, Esumi M, Iwasaki Y, Yanai M, Enomoto A, Kawano K. Phylogenetic evidence, by multiple clone analysis of hypervariable region 1, for the transmission of hepatitis C virus to chronic haemodialysis patients. J Viral Hepat 2000;7:276-82.

  • 150. Izopet J, Pasquier C, Sandres K, Puel J, Rostaing L. Molecular evidence for nosocomial transmission of hepatitis C virus in a French hemodialysis unit. J Med Virol 1999;58:139-44. [Crossref]

  • 151. Savey A, Simon F, Izopet J, Lepoutre A, Fabry J, Desenclos JC. A large nosocomial outbreak of hepatitis C virus infections at a hemodialysis center. Infect Control Hosp Epidemiol 2005;26:752-60.

  • 152. Delarocque-Astagneau E, Baffoy N, Thiers V, Simon N, de Valk H, Laperche S, et al. Outbreak of hepatitis C virus infection in a hemodialysis unit: Potential transmission by the hemodialysis machine? Infect Control Hosp Epidemiol 2002;23:328-34.

  • 153. Jadoul M. Epidemiology and mechanisms of transmission of the hepatitis C virus in haemodialysis. Nephrol Dial Transplant 2000;15:39-41.

  • 154. Jadoul M, Cornu C, van Ypersele de Strihou C. Universal precautions prevent hepatitis C virus transmission: A 54 month follow-up of the Belgian Multicenter Study. The Universitaires Cliniques St-Luc (UCL) Collaborative Group. Kidney Int 1998;53:1022-5. [Crossref]

  • 155. Saxena AK, Panhotra BR. The impact of nurse understaffing on the transmission of hepatitis C virus in a hospital-based hemodialysis unit. Med Princ Pract 2004;13:129-35. [Crossref]

  • 156. Centers for Disease Control (CDC). Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep 2001;50:1-43.

  • 157. Kidney Disease: Improving Global Outcomes (KDIGO).KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl 2008;109:S1-99.

  • 158. Al-Jiffri AM, Fadeg RB, Ghabrah TM, Ibrahim A. Hepatitis C virus infection among patients on HD in Jeddah: A single center experience. Saudi J Kidney Dis Transpl 2003;14:84-9.

  • 159. Goldberg D, Anderson E. Hepatitis C: Who is at risk and how do we identify them? J Viral Hepat 2004;11 Suppl 1:12-8.

  • 160. Mohamed WZ. Prevention of hepatitis C virus in hemodialysis patients: Five years’ experience from a single center. Saudi J Kidney Dis Transpl 2010;21:548-54

  • 161. Au JS, Pockros PJ. Novel Therapeutic Approaches for Hepatitis C, Clinical Pharmacology & Therapeutics advance online publication 27 November 2013.

  • 162. Simmonds P. Genetic diversity and evolution of hepatitis C virus-15 years on. J Gen Virol 2004;85:3173-88. [Crossref]

  • 163. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401. [Crossref]

  • 164. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-206. [Crossref]

  • 165. Poordad F, Dieterich D. Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents. J Viral Hepat 2012;19:449-64.

  • 166. Peck-Radosavljevic M, Boletis J, Besisik F, Ferraz ML, Alric L, Samuel D, et al. Low-dose peginterferon alfa-2a (40KD) is safe and produces a SVR in patients with chronic hepatitis C and end-stage renal disease. Clin Gastroenterol Hepatol 2011;9:242-8.

  • 167. Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, et al. Pegylated interferon-alpha2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther 2000;68:556-67.

  • 168. Fabrizi F, Dixit V, Martin P, Messa P. Combined antiviral therapy of hepatitis C virus in dialysis patients: Meta-analysis of clinical trials. J Viral Hepat 2011;18:e263-9.

  • 169. Dahlan Y, Ather HM, Al-ahmadi M, Batwa F, Al-hamoudi W. Sustained virological response in a predominantly hepatitis C virus genotype 4 infected population. World J Gastroenterol 2009;15:4429-33. [Crossref]

  • 170. Bruchfeld A, Lindahl K, Reichard O, Carlsson T, Schvarcz R. Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. J Viral Hepat 2006;13:316-21.

  • 171. Treitel M, Marbury T, Preston RA, Triantafyllou I, Feely W, O’Mara E, et al. Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function. Clin Pharmacokinet 2012;51:619-28. [Crossref]

  • 172. European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2014;60:392-420.

  • 173. Scheel TK, Rice CM. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med 2013;19:837-49. [Crossref]

About the article

Published Online: 2015-09-30

Published in Print: 2015-09-01



Citation Information: Journal of Translational Internal Medicine, ISSN (Online) 2224-4018, DOI: https://doi.org/10.1515/jtim-2015-0018. Export Citation

© 2015. This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License. (CC BY-NC-ND 3.0)

Comments (0)

Please log in or register to comment.
Log in